Complement Inhibitor Eculizumab in Clinical Islet Transplantation
Status:
Completed
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
This is a dual centre, single arm, exploratory study of the possibility to use eculizumab
(Soliris) to prevent/reduce destruction of islets of Langerhans after portal infusion of the
islets in patients with diabetics accepted for islet transplant.
Phase:
Phase 2
Details
Lead Sponsor:
Uppsala University
Treatments:
Complement Inactivating Agents Complement System Proteins Eculizumab